392 related articles for article (PubMed ID: 27815305)
1. TP53 Mutations in Breast and Ovarian Cancer.
Silwal-Pandit L; Langerød A; Børresen-Dale AL
Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27815305
[TBL] [Abstract][Full Text] [Related]
2. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
3. Expression signatures of TP53 mutations in serous ovarian cancers.
Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
[TBL] [Abstract][Full Text] [Related]
4. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
5. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.
Seagle BL; Eng KH; Dandapani M; Yeh JY; Odunsi K; Shahabi S
Oncotarget; 2015 Jul; 6(21):18641-52. PubMed ID: 26215675
[TBL] [Abstract][Full Text] [Related]
6. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
7. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
8. CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Rajapakshe K; Hawkins SM; Matzuk MM; Milosavljevic A; Yen L
PLoS Genet; 2014 Mar; 10(3):e1004216. PubMed ID: 24675677
[TBL] [Abstract][Full Text] [Related]
9. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer.
Hayano T; Yokota Y; Hosomichi K; Nakaoka H; Yoshihara K; Adachi S; Kashima K; Tsuda H; Moriya T; Tanaka K; Enomoto T; Inoue I
PLoS One; 2014; 9(12):e114491. PubMed ID: 25460179
[TBL] [Abstract][Full Text] [Related]
11. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Feki A; Irminger-Finger I
Crit Rev Oncol Hematol; 2004 Nov; 52(2):103-16. PubMed ID: 15501075
[TBL] [Abstract][Full Text] [Related]
12. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
[TBL] [Abstract][Full Text] [Related]
14. miR-7 expression in serous ovarian carcinomas.
Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
[TBL] [Abstract][Full Text] [Related]
15. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
18. The diagnosis of a metastatic breast tumor from ovarian cancer by the succession of a p53 mutation: a case report.
Mori R; Futamura M; Morimitsu K; Saigo C; Miyazaki T; Yoshida K
World J Surg Oncol; 2017 Jun; 15(1):117. PubMed ID: 28662703
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
Kringen P; Bergamaschi A; Due EU; Wang Y; Tagliabue E; Nesland JM; Nehman A; Tönisson N; Børresen-Dale AL
Biotechniques; 2005 Nov; 39(5):755-61. PubMed ID: 16312222
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]